Intellectus Partners LLC Buys 182 Shares of Cencora, Inc. (NYSE:COR)

Intellectus Partners LLC boosted its stake in Cencora, Inc. (NYSE:COR) by 6.3% in the 3rd quarter, Holdings Channel reports. The firm owned 3,058 shares of the company’s stock after acquiring an additional 182 shares during the quarter. Intellectus Partners LLC’s holdings in Cencora were worth $688,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in COR. Kingsview Wealth Management LLC purchased a new position in Cencora during the first quarter valued at approximately $681,000. Blair William & Co. IL purchased a new stake in shares of Cencora in the 1st quarter valued at about $5,520,000. Orion Portfolio Solutions LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $3,026,000. Dorsey & Whitney Trust CO LLC purchased a new position in shares of Cencora during the first quarter worth about $288,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of Cencora in the first quarter worth approximately $237,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on COR. Wells Fargo & Company lifted their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR opened at $240.24 on Friday. Cencora, Inc. has a 12-month low of $194.23 and a 12-month high of $251.56. The company has a market cap of $47.34 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 1.66 and a beta of 0.44. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The stock has a fifty day simple moving average of $232.62 and a two-hundred day simple moving average of $231.08.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.